Unique ID issued by UMIN | UMIN000023292 |
---|---|
Receipt number | R000017833 |
Scientific Title | The effect of calcium, Vitamin D, and denosumab on osteoporosis and basal metabolism in postmenopausal diabetic women |
Date of disclosure of the study information | 2016/07/22 |
Last modified on | 2017/01/23 17:29:32 |
The effect of calcium, Vitamin D, and denosumab on osteoporosis and basal metabolism in postmenopausal diabetic women
The effect of denosumab on basal metabolism in type 2 diabetic women
The effect of calcium, Vitamin D, and denosumab on osteoporosis and basal metabolism in postmenopausal diabetic women
The effect of denosumab on basal metabolism in type 2 diabetic women
Japan |
Type 2 Diabetes Mellitus, Osteoporosis
Medicine in general | Endocrinology and Metabolism | Orthopedics |
Others
NO
The aim of this study is to evaluate the change of the basal metabolism, glucose control and bone metabolism in patients with type 2 diabetes by improvement of osteoporosis with Calcium/vitamin D and Denosumab.
Efficacy
Confirmatory
Pragmatic
Not applicable
Changes of the Basal metabolism, and the marker of the bone metabolism before and after taking Calcium/Vitamin D and denosumab
Changes of the blood glucose control level, fasting CPR, iPTH, 25hydroxyvitamin D, blood cell count, serum calcium, phosphate and other general examination of blood, and diabetic neuropathy
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Calcium / Vitamin D / Magnesium mixed tablet ; Calcium 305mg, Cholecalciferol 0.005mg (200IU), Magnesium carbonate 59.2mg is containing per tablet. Taking 2 tablet / day prior 1 month from Denosumab 60mg injection to subcutaneous, once per 6 months.
50 | years-old | <= |
100 | years-old | > |
Male and Female
Patient of type 2 Diabetes Mellitus
1: More than 50 years of age at the time of obtaining informed consent
2:With osteoporosis
3: At the participation in this study, that document consent is obtained due to free will of the patient's own by sufficient explanation and thorough understanding.
4:Control of blood pressure and blood glucose are relatively stable, and without planning for remarkable change.
The patients who
Taking drug for osteoporosis
With presence and past history of malignancy.
With other endocrine diseases
With liver dysfunction except fatty liver
With macro proteinuria or with increased serum creatinine level over 2.0mg/dl
Principal investigator of this study has determined to be inappropriate as a subject
50
1st name | |
Middle name | |
Last name | Yasuko Uchigata |
Tokyo Women's Medical University
Diabetes Center
8-1,Kawadacho Shinjyukuku Tokyo 1628666 Japan
03-3353-8111
uchigata.dmc@twmu.ac.jp
1st name | |
Middle name | |
Last name | Makiko Ogata |
Tokyo Women's Medical University
Diabetes Center
8-1,Kawadacho Shinjyukuku Tokyo 1628666 Japan
03-3353-8111
mogatamd.dmc@twmu.ac.jp
Tokyo Women's Mediclcal University
Diabetes Center, Tokyo Women's Medical University
Other
Japan
NO
東京女子医科大学病院糖尿病センター(東京都)
2016 | Year | 07 | Month | 22 | Day |
Unpublished
Enrolling by invitation
2015 | Year | 01 | Month | 20 | Day |
2015 | Year | 03 | Month | 19 | Day |
2017 | Year | 04 | Month | 28 | Day |
2016 | Year | 07 | Month | 22 | Day |
2017 | Year | 01 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017833
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |